Trial Profile
A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms PANDA
- 05 Aug 2021 Planned End Date changed from 1 Dec 2017 to 1 May 2017.
- 05 Aug 2021 Planned primary completion date changed from 1 Oct 2018 to 1 May 2017.
- 05 Aug 2021 Planned initiation date changed from 1 Jun 2015 to 1 Oct 2014.